

REGULATED INFORMATION

**MITHRA PHARMACEUTICALS ANNOUNCES STRENGTHENING OF ITS
MANAGEMENT TEAM**

Liège, Belgium 1 October 2015, 17:45 – Mithra Pharmaceuticals today announces the strengthening of its management team with changes and appointments inside different departments: the appointment of Frederik Vanvoorden as Group Controller and Michael Truyen as new CLO. Eric Van Traelen, who has successfully assumed the role of CLO since 2006, will focus on his new function of Secretary of the Board and support the business development and M&A deals of the company. The Business Development structure will also be restructured and driven by a committee formed by the CEO, François Fornieri, and the CMO, Jan Van der Auwera.

Finance and Accounting Department

Mithra Pharmaceuticals is pleased to announce the appointment of Frederik Vanvoorden as Group Controller. As Group Controller, Frederik will assume and manage the day-to-day financial and accounting control and responsibilities and will report to the Chief Financial Officer, Steven Peters.

Before joining Mithra as Group Controller, Frederik Vanvoorden was Deals Director at PwC Brussels. Frederik Vanvoorden joined PwC Belgium in 2003, providing auditing to industrial companies and service organisations. Since 2007, Frederik has been active in M&A. He has in-depth experience in buy-side and sell-side financial due diligence, vendor due diligence, vendor assistance, carve-outs and business plan reviews advising both financial and corporate investors.

Legal Department

Mithra Pharmaceuticals is pleased to announce that it has strengthened its senior management team by the appointment of a new Chief Legal Officer (CLO), Michael Truyen.

Michael Truyen comes to Mithra after a career of 11 years as a lawyer at Eubelius, Belgium's largest independent law firm (where he was made an associate partner in 2014). His practice there focused on corporate and securities law, including venture capital, public and private securities offerings and mergers & acquisitions. During his career, Michael assisted a number of Belgian knowledge-based and other companies, from start-up companies through listed companies, in various matters, including initial and secondary public offerings, and notably including Mithra's successful IPO on Euronext Brussels. He is a graduate of KULeuven, where he earned masters degrees in both law and business.

At Mithra, he will join the Executive Management Team and head up the legal department. This role has been successfully assumed since 2006 by Eric Van Traelen, who will focus on his new function of Secretary of the Board. He will also support the Business Development structure on strategic aspects

through his strong expertise in structuring and M&A deals. He indeed played a key role in many strategic steps for the company.

Business Development Department

Mithra Pharmaceuticals restructures its Business Development Department by replacing the Chief Business Development Officer (CBDO), function endorsed by Claude Lubicki, by a committee headed by both Chief Executive Officer (CEO), François Fornieri and Chief Marketing Officer (CMO), Jan Van der Auwera. Claude Lubicki will now assume the function of Business Development Consultant.

François Fornieri, CEO said « *In view of the ambition of Mithra Pharmaceuticals in becoming a World leader in Women's Health, it has been decided to strengthen positions at its senior management level to provide the company with the expertise needed for the execution of its strategy* ».

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO/ Steven Peters, CFO/ Julie Dessart, CCO/ Jean-Manuel Fontaine, PRO

+32 4 349 28 22

investorrelations@mithra.com

To subscribe to Mithra's newsletter, visit investors.mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and generic products in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.